Drug Tolerance

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.

Among patients with idiopathic pulmonary fibrosis, 12-week bexotegrast was deemed well tolerated and may have an antifibrotic effect, according to results published in American Journal of Respiratory and Critical Care Medicine.

WASHINGTON — Over 12 or 24 weeks, patients with COPD receiving ensifentrine showed improved measures of lung function, quality of life and exacerbation rate, according to an American Thoracic Society International Conference presentation.

Quarter doses of four antihypertensive medications vs. monotherapy in patients with hypertension.

Use of a “quadpill” capsule containing quarter doses of four antihypertensive medications conferred greater BP reductions compared with monotherapy, with similar safety and tolerability, a speaker reported.

Efficacy of dapagliflozin (Farxiga, AstraZeneca) in patients with cardiometabolic risk factors hospitalized with COVID-19.

The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo, though data showed lower event numbers among treated patients.

CHICAGO — In this video exclusive, Cardiology Today Editorial Board Member Ileana L. Piña, MD, MPH, discussed her Cardiometabolic Health Congress workshop on the role of potassium-binding agents in optimizing guideline-directed therapy for HF.